Iron and Clinical Outcomes in Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients

Advances in Chronic Kidney Disease

Volumn 16, Issue 2, 2009, Pages 109-116

  Kovesdy, Csaba P ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Ferritin; Iron; Mortality; Outcomes; Transferrin saturation

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; PROTOPORPHYRIN ZINC; TRANSFERRIN RECEPTOR;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIALYSIS; DRUG MEGADOSE; ERYTHROCYTE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS PATIENT; HOMEOSTASIS; HUMAN; IRON DEFICIENCY; IRON STORAGE; PREVALENCE; PRIORITY JOURNAL;

ERYTHROPOIESIS; FERRITINS; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; SURVIVAL RATE; TRANSFERRIN; UNITED STATES;

EID: 60149092184     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.12.006     Document Type: Article

References (69)

1. Rouault T.A. How mammals acquire and distribute iron needed for oxygen-based metabolism. PLoS Biol 1 (2003) e79
2. II. Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults. Am J Kidney Dis 47 (2006) S16
3. Eschbach J.W., and Adamson J.W. Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney Int 55 (1999) S35-S43
4. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 27 (2007) 565-571
5. Beallo R., Dallman P.R., Schoenfeld P.Y., et al. Serum ferritin and iron deficiency in patients on chronic hemodialysis. Trans Am Soc Artif Intern Organs 22 (1976) 73-79
6. Fernandez-Rodriguez A.M., Guindeo-Casasus M.C., Molero-Labarta T., et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 34 (1999) 508-513
7. Kalantar-Zadeh K., Hoffken B., Wunsch H., et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 (1995) 292-299
8. Canavese C., Bergamo D., Ciccone G., et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65 (2004) 1091-1098
9. Fishbane S., Shapiro W., Dutka P., et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60 (2001) 2406-2411
10. Kaneko Y., Miyazaki S., Hirasawa Y., et al. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 63 (2003) 1086-1093
11. Asanuma M., Taguchi C., Uesaka H., et al. Discrepancy between the percentage of hypochromic erythrocytes and the reticulocyte hemoglobin content in hemodialysis patients with recombinant human erythropoietin therapy. Lab Hematol 11 (2005) 124-130
12. Bovy C., Tsobo C., Crapanzano L., et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 56 (1999) 1113-1119
13. Chiang W.C., Tsai T.J., Chen Y.M., et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58 (2002) 363-369
14. Canavese C., Grill A., Decostanzi E., et al. Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients. Clin Nephrol 53 (2000) 42-47
15. Malyszko J., Malyszko J.S., Hryszko T., et al. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?. Am J Nephrol 25 (2005) 586-590
16. Fishbane S., Kowalski E.A., Imbriano L.J., et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7 (1996) 2654-2657
17. Tessitore N., Solero G.P., Lippi G., et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16 (2001) 1416-1423
18. Gunnell J., Yeun J.Y., Depner T.A., et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
19. Kalantar-Zadeh K., Rodriguez R.A., and Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 141-149
20. Harrison P.M., and Arosio P. The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275 (1996) 161-203
21. Kwak E.L., Larochelle D.A., Beaumont C., et al. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem 270 (1995) 15285-15293
22. Rogers J.T., Bridges K.R., Durmowicz G.P., et al. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 265 (1990) 14572-14578
23. Andrews N.C. The iron transporter DMT1. Int J Biochem Cell Biol 31 (1999) 991-994
24. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
25. Ludwiczek S., Aigner E., Theurl I., et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101 (2003) 4148-4154
26. Kalantar-Zadeh K., Kalantar-Zadeh K., and Lee G.H. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Nephrol 1 Suppl 1 (2006) S9-S18
27. Koch K.M., Bechstein P.B., Fassbinder W., et al. Occult blood loss and iron balance in chronic renal failure. Proc Eur Dial Transplant Assoc 12 (1976) 362-369
28. Lindsay R.M., Burton J.A., King P., et al. The measurement of dialyzer blood loss. Clin Nephrol 1 (1973) 24-28
29. Longnecker R.E., Goffinet J.A., and Hendler E.D. Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 20A (1974) 135-140
30. Delano B.G., Manis J.G., and Manis T. Iron absorption in experimental uremia. Nephron 19 (1977) 26-31
31. Goch J., Birgegard G., Danielson B.G., et al. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 73 (1996) 403-406
32. United States Renal Data System: The USRDS Dialysis Morbidity and Mortality Study (wave 1). 45-67. 1996. U.S. Renal Data System 1996Annual Report 4, Bethesda, MD, National Institute of Health, National Institute of Diabetes, Digestive and Kidney Diseases
33. Hsu C.Y., McCulloch C.E., and Curhan G.C. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13 (2002) 2783-2786
34. Gotloib L., Silverberg D., Fudin R., et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19 (2006) 161-167
35. Kovesdy C.P., Estrada W., Ahmadzadeh S., et al. Association of markers of iron stores with outcomes in patients with non-dialysis dependent CKD. Clin J Am Soc Nephrol (2009) (in press)
36. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., et al. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 43 (2004) 671-684
37. Kalantar-Zadeh K., Don B.R., Rodriguez R.A., et al. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37 (2001) 564-572
38. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
39. Ali M., Rigolosi R., Fayemi A.O., et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1 (1982) 652-655
40. Aljama P., Ward M.K., Pierides A.M., et al. Serum ferritin concentration: A reliable guide to iron overload in uremic and hemodialyzed patients. Clin Nephrol 10 (1978) 101-104
41. Baker L.R., Barnett M.D., Brozovic B., et al. Hemosiderosis in a patient on regular hemodialysis: Treatment by desferrioxamine. Clin Nephrol 6 (1976) 326-328
42. Gokal R., Millard P.R., Weatherall D.J., et al. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload. Q J Med 48 (1979) 369-391
43. Nomura S., Osawa G., and Karai M. Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin. Nephron 55 (1990) 210-213
44. Onoyama K., Nakamura S., Yamamoto M., et al. Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: Confirmation by follow-up liver biopsy. Nephron 56 (1990) 325-328
45. Pitts T.O., and Barbour G.L. Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients. Nephron 22 (1978) 316-321
46. Stanbaugh G.H., Gillit D.M., and Holmes A.W. Dialysis hemosiderosis mimicking non-A, non-B hepatitis. Trans Am Soc Artif Intern Organs 30 (1984) 217-221
47. Van de Vyver F.L., Vanheule A.O., Verbueken A.H., et al. Patterns of iron storage in patients with severe renal failure. Contrib Nephrol 38 (1984) 153-166
48. Gonzalez-Michaca L., Farrugia G., Croatt A.J., et al. Heme: A determinant of life and death in renal tubular epithelial cells. Am J Physiol Renal Physiol 286 (2004) F370-F377
49. Zhou X.J., Laszik Z., Wang X.Q., et al. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 80 (2000) 1905-1914
50. Rao M., Wong C., Kanetsky P., et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 72 (2007) 549-556
51. Yilmaz M.I., Carrero J.J., Axelsson J., et al. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: Sources and consequences. Clin Nephrol 68 (2007) 1-9
52. Aggarwal H.K., Nand N., Singh S., et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51 (2003) 170-174
53. Charytan C., Schwenk M.H., Al-Saloum M.M., et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 96 (2004) c63-c66
54. Charytan C., Qunibi W., and Bailie G.R. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100 (2005) c55-c62
55. Spinowitz B.S., Kausz A.T., Baptista J., et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19 (2008) 1599-1605
56. Stoves J., Inglis H., and Newstead C.G. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16 (2001) 967-974
57. Van Wyck D.B., Roppolo M., Martinez C.O., et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68 (2005) 2846-2856
58. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
59. Fudin R., Jaichenko J., Shostak A., et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79 (1998) 299-305
60. Fishbane S. Safety in iron management. Am J Kidney Dis 41 (2003) 18-26
61. Zager R.A., Johnson A.C., Hanson S.Y., et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40 (2002) 90-103
62. Zager R.A., Johnson A.C., and Hanson S.Y. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65 (2004) 2108-2112
63. Agarwal R., Vasavada N., Sachs N.G., et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
64. Michelis R., Gery R., Sela S., et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 18 (2003) 924-930
65. Agarwal R., Rizkala A.R., Kaskas M.O., et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72 (2007) 638-642
66. Seifert A. von HD, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65 (1987) 1015-1024
67. Waterlot Y., Cantinieaux B., Hariga-Muller C., et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J 291 (1985) 501-504 Clin Res Ed
68. Feldman H.I., Santanna J., Guo W., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 (2002) 734-744
69. Feldman H.I., Joffe M., Robinson B., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15 (2004) 1623-1632